Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | LDHA | P00338 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3628705 | 0.83 | HTT (0.68) | HTTSMN1; SMN2CTBP2LDHAALDH1A1 | |
| SCHEMBL240822 | 0.81 | KDM4E (0.74) | HTTSMN1; SMN2CTBP2LDHAALDH1A1 | |
| SCHEMBL1525068 | 0.81 | HTT (0.66) | HTTSMN1; SMN2CTBP2LDHAALDH1A1 | |
| SCHEMBL48525 | 0.81 | HTT (0.66) | HTTSMN1; SMN2CTBP2LDHAALDH1A1 | |
| SCHEMBL28709451 | 0.81 | HTT (0.66) | HTTSMN1; SMN2CTBP2LDHAALDH1A1 | |
| SCHEMBL10969285 | 0.81 | ALDH1A1 (0.55) | HTTSMN1; SMN2CTBP2ALDH1A1CYP3A4 | |
| SCHEMBL2487562 | 0.80 | F2RL1 (0.68) | SMN1; SMN2ALDH1A1KDM4EPOLBF2RL1 | |
| SCHEMBL11531056 | 0.80 | LMNA (0.53) | SMN1; SMN2ALDH1A1CYP3A4TP53KDM4E | |
| SCHEMBL6709316 | 0.80 | NQO1 (0.54) | SMN1; SMN2ALDH1A1CYP2C19KDM4EPOLB | |
| SCHEMBL226124 | 0.79 | HTT (0.63) | HTTSMN1; SMN2CTBP2LDHAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2182950-B1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LTD (GB) | 2017-07-19 | — | — | EP | claimed |
| US-20060106037-A1 | Purin-6-one-derivatives | ALTANA PHARMA AG (DE) | 2006-05-18 | — | — | US | claimed |
| EP-1601675-A1 | PURIN-6-ONE-DERIVATIVES | ALTANA Pharma AG (DE) | 2005-12-07 | — | — | EP | claimed |
| WO-2004089953-A1 | PURIN-6-ONE-DERIVATIVES | ALTANA PHARMA AG (DE) | 2004-10-21 | — | — | WO | claimed |
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| WO-2004018428-A1 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| EP-2182950-B1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LTD (GB) | 2017-07-19 | — | — | EP | disclosed |
| US-8759348-B2 | Use of 4-(pyrrolidin-1-yl)quinoline compounds to kill clinically latent microorganisms | HELPERBY THERAPEUTICS LIMITED (GB) | 2014-06-24 | — | — | US | disclosed |
| US-8394974-B2 | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20100305065-A1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | HELPERBY THERAPEUTICS LIMITED (GB) | 2010-12-02 | — | — | US | disclosed |
| EP-2182950-A1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | Helperby Therapeutics Limited (GB) | 2010-05-12 | — | — | EP | disclosed |
| EP-2003135-A9 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMENE OXIDE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-4166816-A | CYCLIZATION | SMITHKLINE CORPORATION (US) | 1979-09-04 | — | — | US | disclosed |
| US-4144391-A | REPLACING AN ACETOXY GROUP BY A SULFUR NUCLEOPHILE | ELI LILLY AND COMPANY (US) | 1979-03-13 | — | — | US | disclosed |
| US-4133808-A | 4-(Formylthio)azetidinones and ozonization process therefor | ELI LILLY AND COMPANY (US) | 1979-01-09 | — | — | US | disclosed |
| US-4072674-A | FOR CEPHALOSPORIN CONGENERS | SMITHKLINE CORPORATION (US) | 1978-02-07 | — | — | US | disclosed |
| US-4048157-A | 4(Formylthio)-azetidin-2-ones and ozonization process therefor | ELI LILLY AND COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
| US-4031084-A | Process for cephalosporin antibiotic intermediates | ELI LILLY AND COMPANY (US) | 1977-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305065-A1 | USE OF 4-(PYRROLIDIN-1-YL)QUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS | ARG1, LPO, CTSL | HTT 3747/4885SMN1; SMN2 4312/4885CTBP2 4595/4885 |
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | HTT 2287/4885SMN1; SMN2 2635/4885CTBP2 956/4885 |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | HTT 1599/4885SMN1; SMN2 2022/4885CTBP2 1195/4885 |
| US-20060106037-A1 | Purin-6-one-derivatives | PDE4B, PDE4A, PDE2A | HTT 3784/4885SMN1; SMN2 2626/4885CTBP2 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.